160 related articles for article (PubMed ID: 23770010)
21. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers.
Smith TT; Stephan SB; Moffett HF; McKnight LE; Ji W; Reiman D; Bonagofski E; Wohlfahrt ME; Pillai SPS; Stephan MT
Nat Nanotechnol; 2017 Aug; 12(8):813-820. PubMed ID: 28416815
[TBL] [Abstract][Full Text] [Related]
22. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.
Zhu EF; Gai SA; Opel CF; Kwan BH; Surana R; Mihm MC; Kauke MJ; Moynihan KD; Angelini A; Williams RT; Stephan MT; Kim JS; Yaffe MB; Irvine DJ; Weiner LM; Dranoff G; Wittrup KD
Cancer Cell; 2015 Apr; 27(4):489-501. PubMed ID: 25873172
[TBL] [Abstract][Full Text] [Related]
23. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy.
Kim J; Li WA; Choi Y; Lewin SA; Verbeke CS; Dranoff G; Mooney DJ
Nat Biotechnol; 2015 Jan; 33(1):64-72. PubMed ID: 25485616
[TBL] [Abstract][Full Text] [Related]
24. Antigen delivery by lipid-enveloped PLGA microparticle vaccines mediated by in situ vesicle shedding.
Hanson MC; Bershteyn A; Crespo MP; Irvine DJ
Biomacromolecules; 2014 Jul; 15(7):2475-81. PubMed ID: 24894061
[TBL] [Abstract][Full Text] [Related]
25. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
[TBL] [Abstract][Full Text] [Related]
26. Discovering cancer immunotherapy targets in vivo.
Zhou P; Wucherpfennig KW
Oncoimmunology; 2014; 3():e28500. PubMed ID: 25050218
[TBL] [Abstract][Full Text] [Related]
27. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.
Moynihan KD; Opel CF; Szeto GL; Tzeng A; Zhu EF; Engreitz JM; Williams RT; Rakhra K; Zhang MH; Rothschilds AM; Kumari S; Kelly RL; Kwan BH; Abraham W; Hu K; Mehta NK; Kauke MJ; Suh H; Cochran JR; Lauffenburger DA; Wittrup KD; Irvine DJ
Nat Med; 2016 Dec; 22(12):1402-1410. PubMed ID: 27775706
[TBL] [Abstract][Full Text] [Related]
28. Delivering safer immunotherapies for cancer.
Milling L; Zhang Y; Irvine DJ
Adv Drug Deliv Rev; 2017 May; 114():79-101. PubMed ID: 28545888
[TBL] [Abstract][Full Text] [Related]
29. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.
Wilkerson A; Kim J; Huang AY; Zhang M
Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974
[TBL] [Abstract][Full Text] [Related]
30. Synthetic Nanoparticles for Vaccines and Immunotherapy.
Irvine DJ; Hanson MC; Rakhra K; Tokatlian T
Chem Rev; 2015 Oct; 115(19):11109-46. PubMed ID: 26154342
[No Abstract] [Full Text] [Related]
31. Engineering synthetic vaccines using cues from natural immunity.
Irvine DJ; Swartz MA; Szeto GL
Nat Mater; 2013 Nov; 12(11):978-90. PubMed ID: 24150416
[TBL] [Abstract][Full Text] [Related]
32. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination.
Li AV; Moon JJ; Abraham W; Suh H; Elkhader J; Seidman MA; Yen M; Im EJ; Foley MH; Barouch DH; Irvine DJ
Sci Transl Med; 2013 Sep; 5(204):204ra130. PubMed ID: 24068737
[TBL] [Abstract][Full Text] [Related]
33. In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes.
Rüger R; Tansi FL; Rabenhold M; Steiniger F; Kontermann RE; Fahr A; Hilger I
J Control Release; 2014 Jul; 186():1-10. PubMed ID: 24810115
[TBL] [Abstract][Full Text] [Related]
34. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery.
Tang L; Zheng Y; Melo MB; Mabardi L; Castaño AP; Xie YQ; Li N; Kudchodkar SB; Wong HC; Jeng EK; Maus MV; Irvine DJ
Nat Biotechnol; 2018 Sep; 36(8):707-716. PubMed ID: 29985479
[TBL] [Abstract][Full Text] [Related]
35. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.
Schmid D; Park CG; Hartl CA; Subedi N; Cartwright AN; Puerto RB; Zheng Y; Maiarana J; Freeman GJ; Wucherpfennig KW; Irvine DJ; Goldberg MS
Nat Commun; 2017 Nov; 8(1):1747. PubMed ID: 29170511
[TBL] [Abstract][Full Text] [Related]
36. Enhancing cancer immunotherapy with nanomedicine.
Irvine DJ; Dane EL
Nat Rev Immunol; 2020 May; 20(5):321-334. PubMed ID: 32005979
[TBL] [Abstract][Full Text] [Related]
37. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity.
Zhang Y; Li N; Suh H; Irvine DJ
Nat Commun; 2018 Jan; 9(1):6. PubMed ID: 29295974
[TBL] [Abstract][Full Text] [Related]
38. Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies.
Zhang F; Stephan SB; Ene CI; Smith TT; Holland EC; Stephan MT
Cancer Res; 2018 Jul; 78(13):3718-3730. PubMed ID: 29760047
[TBL] [Abstract][Full Text] [Related]
39. CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction.
Siriwon N; Kim YJ; Siegler E; Chen X; Rohrs JA; Liu Y; Wang P
Cancer Immunol Res; 2018 Jul; 6(7):812-824. PubMed ID: 29720380
[TBL] [Abstract][Full Text] [Related]
40. A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors.
Paun RA; Jurchuk S; Tabrizian M
Bioeng Transl Med; 2024 Mar; 9(2):e10601. PubMed ID: 38435821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
